Sample size determination for clinical trials with co-primary outcomes: Exponential event times

Pharmaceutical Statistics

Volumn 12, Issue 1, 2013, Pages 28-34

  Hamasaki, Toshimitsu ^a   Sugimoto, Tomoyuki ^b   Evans, Scott ^c   Sozu, Takashi ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

bivariate exponential distribution; co primary endpoints; conjunctive power; copula; log transformed hazard ratio; right censored; type II error rate

Indexed keywords

ARTICLE; CENSORSHIP; CLINICAL TRIAL (TOPIC); INFECTION; METHODOLOGY; SAMPLE SIZE; TREATMENT OUTCOME;

COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, STATISTICAL; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872494740     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1545     Document Type: Article

References (38)

1. Gong J, Pinheiro JC, DeMets DL,. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Controlled Clinical Trials 2000; 21: 323-329. DOI: 10.1016/S0197-2456(00)00049-0.
2. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, Sankoh AJ, Wang J, Yeh CH,. Multiple co-primary endpoints: medical and statistical solutions. Drug Information Journal 2007; 41: 31-46. DOI: 10.1177/009286150704100105.
3. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W,. Challenge of multiple co-primary endpoints: a new approach. Statistics in Medicine 2007; 26: 1181-1192. DOI: 10.1002/sim.2604.
4. Hung HMJ, Wang SJ,. Some controversial multiple testing problems in regulatory applications. Journal of Biopharmaceutical Statistics 2009; 19: 1-11. DOI: 10.1080/10543400802541693.
5. Dmitrienko A, Tamhane AC, Bretz F,. Multiple Testing Problems in Pharmaceutical Statistics. Chapman & Hall: Boca Raton, FL, 2010.
6. Sugimoto T, Hamasaki T, Sozu T,. Sample size determination in clinical trials with two correlated co-primary time-to-event endpoints. Abstract of the 7th International Conference on Multiple Comparison Procedure, 121, Washington DC, USA, 29 August-1 September 2011.
7. Sugimoto T, Hamasaki T, Sozu T, Evans S,. Sample size determination in clinical trials with two correlated time-to-events endpoints as primary contrasts. The 6th Annual FDA-DIA Statistics Forum, Bethesda, United States, 23-25 April 2012.
8. Cox DR, Oakes D,. Analysis of Survival Data. Chapman & Hall: Boca Raton, FL, 1984.
9. Kotz S, Johnson NL, Balakrishnan N,. Continuous Multivariate Distributions: Models and Applications. John Wiley & Sons: New York, 2000.
10. Clayton DG,. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease. Biometrika 1976; 65: 141-151. DOI: 10.1093/biomet/65.1.141.
11. Hougaard P,. Life table methods for heterogeneous populations: distributions describing the heterogeneity. Biometrika 1984; 71: 75-83. DOI: 10.1093/biomet/71.1.75.
12. Hougaard P,. A class of multivariate failure time distribution. Biometrika 1986; 73: 671-678. DOI: 10.1093/biomet/73.3.671.
13. Frank MJ,. On the simultaneous associativity of F(x,y) and x + y-F(x,y). Aequationes Mathematicae 1979; 19: 194-226. DOI: 10.1007/BF02189866.
14. Genest C,. Frank's family of bivariate distribution. Biometrika 1987; 74: 549-555. DOI: 10.1093/biomet/74.3.549.
15. Hsu L, Prentice RL,. On assessing the strength of dependency between failure time variables. Biometrika 1996; 83: 491-506. DOI: 10.1093/biomet/83.3. 491.
16. Jung SH,. Sample size calculation for the weighted rank statistics with paired survival data. Statistics in Medicine 2009; 27: 3350-3365. DOI: 10.1002/sim.3189.
17. Prentice RL, Cai J,. Covariance and survivor function estimation using censored multivariate failure time data. Biometrika 1992; 73: 495-512. DOI: 10.1093/biomet/79.3.495.
18. Marshall AW, Olkin I,. A multivariate exponential distribution. Journal of the American Statistical Association 1967; 62: 30-44. DOI: 10.1080/01621459.1967.10482885.
19. Marshall AW, Olkin I,. A generalized bivariate exponential distribution. Journal of Applied Probability 1967; 4: 291-302.
20. Fleischer F, Gaschler-Markefski B, Bluhmki E,. A statistical model for the dependence between progression-free survival and overall survival. Statistics in Medicine 2009; 28: 2669-2686. DOI: 10.1002/sim.3637.
21. Rosenkranz GK,. Another view on the analysis of cardiovascular morbidity/mortality trials. Pharmaceutical Statistics 2011; 10: 196-202. DOI: 10.1002/pst.434.
22. Machin D, Campbell MJ, Tan SB, Tan SH,. Sample Size Tables for Clinical Studies, 3rd Edition. John Wiley & Sons: Chichester, 2009.
23. Collett D,. Modelling Survival Data in Medical Research, 2nd Edition. Chapman & Hall: Boca Raton, FL, 2003.
24. Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y,. Multiple Comparisons and Multiple Tests Using the SAS System. SAS: Cary NC, 1999.
25. Senn S, Bretz F,. Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics 2007; 6: 161-170. DOI: 10.1002/pst.301.
26. Bretz F, Hothorn T, Westfall P,. Multiple Comparisons Using R. Chapman & Hall: Boca Raton, FL, 2011.
27. Gross AJ, Clark VA,. Survival Distributions: Reliability Applications in the Biomedical Science. John Wiley & Sons: New York, 1975.
28. Lachin E,. Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 1981; 2: 93-113. DOI: 10.1016/0197-2456(81)90001-5.
29. Fleiss JL, Levin B, Paik MC,. Statistical Methods for Rates and Proportions. John Wiley & Sons: New York, 2003.
30. Sugimoto T, Sozu T, Hamasaki T,. A convenient formula for calculating sample size of clinical trials with multiple co-primary continuous endpoints. Pharmaceutical Statistics 2012; 11: 118-128. DOI: 10.1002/pst.505.
31. Fletcher R,. Practical Methods of Optimization: Constrained Optimization, Vol. 2. John Wiley & Sons: Chichester, 1981.
32. Gill PE, Murray W, Wright M,. Practical Optimization. Academic Press: London, 1981.
33. Lee ET, Desu MM, Gehan EA,. A Monte Carlo study of the power of same two-sample tests. Biometrika 1975; 62: 425-432. DOI: 10.1093/biomet/62.2.425.
34. Peace KE, Flora RE,. Size and power assessments of tests of hypotheses on survival parameters. Journal of the American Statistical Association 1978; 73: 129-132. DOI: 10.1080/01621459.1978.10480015.
35. Kellerer AM, Chmelevsky D,. Small-sample properties of censored-data rank tests. Biometrics 1983; 39: 675-682.
36. Sozu T, Sugimoto T, Hamasaki T,. Sample size determination in clinical trials with multiple co-primary binary endpoints. Statistics in Medicine 2010; 29: 2169-2179. DOI: 10.1002/sim.3972.
37. Sozu T, Sugimoto T, Hamasaki T,. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. Journal of Biopharmaceutical Statistics 2011; 21: 650-668. DOI: 10.1080/10543406.2011. 551329.
38. Sozu T, Sugimoto T, Hamasaki T,. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Biometrical Journal 2012; 54: 716-729. DOI: 10.1002/bimj.201100221.